Reading Time: 7 minutesEach year we invite plenary speakers who are experts in their fields to provide an overview on topics across MND research and clinical practice. This year we have 14 plenary speakers talking about ALS/MND who will discuss a wide range of topics from genetics to tissue biomarkers to improving clinical practice. In this second blog we will be taking a closer look at some of our plenary speakers this year and sharing more about the topics they will be discussing.
Search Results for: clinical trial
Reading Time: 4 minutesMy name is Florence and I’m doing a PhD in artificial intelligence (AI) enabled healthcare at University College London. My research is specifically investigating how AI techniques can be used to improve the prediction of how quickly somebody’s disease will progress in motor neurone disease.
Reading Time: 5 minutesHi there! I’m Dezerae, and I am currently a Lady Edith Wolfson Junior Non-Clinical Research Fellow at the University of Cambridge. My work, supported by
A stepping stone to becoming future leaders in MND research
Reading Time: 6 minutesMND is a very complex disease and collaboration within the research community is key to building on our current understanding of the disease biology and
Reading Time: 12 minutesDespite decades of research, we still do not fully understand why some people get MND, but studies in cell and animal models of the disease
Reading Time: 4 minutesLast month we hosted the second MND EnCouRage UK event for early career researchers (ECRs) which aims to support them to continue working in the
Highlights from MND EnCouRage UK 2023
Reading Time: 5 minutesHi everyone! My name’s Katie and I recently joined the Association as a Supporter Information Officer. My role offers me a unique perspective as I
Reading Time: 6 minutesMND is a very complex disease, and in the UK there is still only one approved treatment so the need for more effective treatments remains
Reading Time: 5 minutesThe current pace of clinical trials means that there are now more trials testing potential drugs for MND in the UK than ever before. One